Healthcare
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-yearPurified Cortrophin® Gel net revenues of $117.1 million, an increase of 43.5% year-over-yearQuarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-yearDiluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 mil
About this update from Ani Pharmaceuticals, Inc.
PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026. "In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history," said Nikhil Lalwani, President and CEO of ANI. "Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing. The encouraging initial trends we are seeing from the gout expansion, and the continued momentum in our existing specialties, further support our conviction in Cortrophin Gel's sizable multi-year growth opportunity." "We are reaffirming our full year 2026 total net revenue guidance of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million. Based on our results in the first half of 2026, we are modestly adjusting our Cortrophin Gel net revenue guidance to $520 - $540 million, reflecting 50-55% growth for the full year. Our solid track record of commercial execution and prudent capital allocation combined with our strong balance sheet position us well for continued shareholder value creation," he concluded. Second Quarter and Recent Business Highlights: Rare Disease Generics Brand Royalties and Other Revenues Brands Corporate Highlights Second Quarter 2026 Financial Results (1) There were no sales of YUTIQ during the quarter ended June 30, 2026, as the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN, which has a combined label of DME and NIU-PS during the second quarter of 2025. All comparisons are made versus the same period in 2025 unless otherwise stated. Total net revenues for the second quarter of 2026 were $266.0 million, an increase of 25.9% over the prior year period. Net revenues for Rare Disease, which includes Cortrophin Gel and ILUVIEN, increased 30.7% to $135.8 million. Cortrophin Gel net revenues increased 43.5% to $117.1 million and ILUVIEN net revenues decreased 16.1% to $18.7 million. Growth for Cortrophin was driven primarily by increased volume while ILUVIEN was impacted by timing of shipments in certain international markets. Net revenues for Brands decreased 10.5% to $11.8 million dr...
View stock analysis, news, and events for Ani Pharmaceuticals, Inc.